
|Articles|January 1, 2007
Propecia suppresses PSA
Dallas - Low-dose Propecia (finasteride, Merck), used to treat hair loss, appears to suppress prostate specific antigen (PSA) levels, which could skew results of prostate cancer tests, researchers say.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
AbbVie Files for Vitiligo Indication, Putting Systemic Therapy Under Regulatory Review
2
UCB Presents 3-Year BE HEARD Trial Results for Bimekizumab in Moderate-to-Severe HS
3
Nutrafol Expands Portfolio with First and Only Hair Loss Supplement for Male Patients 50 and Older
4
World Cancer Day 2026: La Roche-Posay and ONS Partner to Launch Skin of Color Toxicity Repository
5











